Zacks Investment Research upgraded shares of Organovo (NASDAQ:ONVO) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, Zacks.com reports. The brokerage currently has $0.50 target price on the medical research company’s stock.

According to Zacks, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. “

Organovo stock opened at $0.55 on Thursday. Organovo has a twelve month low of $0.37 and a twelve month high of $1.97. The company has a market cap of $96.25 million, a PE ratio of -1.73 and a beta of 1.79.

Several hedge funds have recently made changes to their positions in ONVO. BlackRock Inc. lifted its stake in shares of Organovo by 1.5% during the 3rd quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock valued at $8,129,000 after buying an additional 102,486 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Organovo by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after buying an additional 52,073 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of Organovo by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after buying an additional 52,073 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Organovo by 53.0% during the 4th quarter. Rhumbline Advisers now owns 143,143 shares of the medical research company’s stock valued at $137,000 after buying an additional 49,579 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Organovo by 86.5% during the 4th quarter. SG Americas Securities LLC now owns 77,206 shares of the medical research company’s stock valued at $74,000 after buying an additional 35,818 shares in the last quarter. Institutional investors own 43.01% of the company’s stock.

About Organovo

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: Short Selling

Get a free copy of the Zacks research report on Organovo (ONVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.